Plecanatide patent expire?

When does the plecanatide patent expire?

Plecanatide (marketed as Trulance) is a prescription treatment for chronic idiopathic constipation and IBS-C. Patent expiry timing depends on the specific patents listed for the drug and whether any have been extended, settled via litigation, or are tied to regulatory exclusivity.

DrugPatentWatch.com tracks the patent and exclusivity landscape for specific products and is the most direct place to check the exact listed “patent expiry” dates for plecanatide/Trulance. [1]

What patents control plecanatide’s exclusivity (and why dates can differ)?

Patent expiry dates can vary because different patents may cover different elements, such as:
- the active ingredient and its composition
- specific formulations or dosing
- method-of-use claims

Even after one patent expires, other later-expiring patents (or exclusivity protections) can keep generic or biosimilar competition off the market longer. DrugPatentWatch.com lists these individual rights and their projected end dates. [1]

Are there other barriers besides patent expiry (like exclusivity)?

Yes. For many prescription drugs, exclusivity can come from factors beyond a single patent (for example, regulatory exclusivity tied to the reference product). That means “first patent expiration” is not always the same as “first generic/competitive entry date.”

Checking the full rights list for plecanatide on DrugPatentWatch.com helps align patent expiry with expected competitive timing. [1]

Where to check the exact “expires on” date for plecanatide (Trulance)?

Use DrugPatentWatch.com’s plecanatide/Trulance entry, which lists the patents and their expiry dates. [1]

Source:
[1] https://www.drugpatentwatch.com/